CA3198258A1 - Medicine for alleviating neuropathic pain - Google Patents

Medicine for alleviating neuropathic pain

Info

Publication number
CA3198258A1
CA3198258A1 CA3198258A CA3198258A CA3198258A1 CA 3198258 A1 CA3198258 A1 CA 3198258A1 CA 3198258 A CA3198258 A CA 3198258A CA 3198258 A CA3198258 A CA 3198258A CA 3198258 A1 CA3198258 A1 CA 3198258A1
Authority
CA
Canada
Prior art keywords
receptor
hydroxymethyl
carboxamide
hydroxy
tetrahydroquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198258A
Other languages
English (en)
French (fr)
Inventor
Yosuke Imai
Hikaru Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3198258A1 publication Critical patent/CA3198258A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3198258A 2020-11-30 2021-11-26 Medicine for alleviating neuropathic pain Pending CA3198258A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-199206 2020-11-30
JP2020199206 2020-11-30
PCT/JP2021/043375 WO2022114122A1 (ja) 2020-11-30 2021-11-26 神経障害性疼痛を緩和させるための医薬

Publications (1)

Publication Number Publication Date
CA3198258A1 true CA3198258A1 (en) 2022-06-02

Family

ID=81755628

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198258A Pending CA3198258A1 (en) 2020-11-30 2021-11-26 Medicine for alleviating neuropathic pain

Country Status (11)

Country Link
US (1) US20240009180A1 (https=)
EP (1) EP4272758A4 (https=)
JP (1) JPWO2022114122A1 (https=)
KR (1) KR20230096055A (https=)
CN (1) CN116782901A (https=)
AU (1) AU2021389409A1 (https=)
CA (1) CA3198258A1 (https=)
IL (1) IL302972A (https=)
MX (1) MX2023006289A (https=)
TW (1) TW202237111A (https=)
WO (1) WO2022114122A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121159455A (zh) * 2024-06-18 2025-12-19 武汉人福创新药物研发中心有限公司 氨基酯类化合物及其作为p2x7拮抗剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013269606B2 (en) 2012-06-01 2018-05-17 Ablynx N.V. P2X7 receptor antagonists and agonists
JP6301920B2 (ja) 2013-05-27 2018-03-28 国立大学法人 岡山大学 疼痛治療薬
US11077100B2 (en) * 2017-03-13 2021-08-03 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as P2X7 receptor antagonists
EP3398941A1 (en) 2017-05-03 2018-11-07 AXXAM S.p.A. Heterocyclic p2x7 antagonists
JP7311944B2 (ja) 2018-04-16 2023-07-20 塩野義製薬株式会社 二環性含窒素複素環誘導体を含有する医薬組成物
JP2019182806A (ja) 2018-04-16 2019-10-24 塩野義製薬株式会社 二環性複素環誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
CN116782901A (zh) 2023-09-19
WO2022114122A1 (ja) 2022-06-02
US20240009180A1 (en) 2024-01-11
KR20230096055A (ko) 2023-06-29
EP4272758A1 (en) 2023-11-08
EP4272758A4 (en) 2025-01-29
JPWO2022114122A1 (https=) 2022-06-02
IL302972A (en) 2023-07-01
MX2023006289A (es) 2023-07-31
TW202237111A (zh) 2022-10-01
AU2021389409A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
Bonaventure et al. Selective blockade of 5-hydroxytryptamine (5-HT) 7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents
Thomas et al. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications
JP6895252B2 (ja) 心筋ｉｋｒチャネルの薬剤誘発性阻害のリポソームによる軽減
US20210401776A1 (en) Method of treating refractory epilepsy syndromes using fenfluramine enantiomers
Natera-de Benito et al. Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations
KR20100127799A (ko) 세로토닌 운반체 유전자 및 알콜중독의 치료
EP3846810B1 (en) Chronic nightly dosing of lasmiditan for migraine prevention
US20240009180A1 (en) Medicine for alleviating neuropathic pain
US20100260772A1 (en) Methods for treating or preventing diseases associated with low bone mass
EP3156054A1 (en) Medicine for preventing and/or treating stress-induced diseases
Joo et al. A novel point mutation in PMP22 gene associated with a familial case of Charcot-Marie-Tooth disease type 1A with sensorineural deafness
JP7088628B2 (ja) うつ病や急性ストレス障害の診断バイオマーカー及び治療又は予防用組成物
HK40094114A (en) Medicine for alleviating neuropathic pain
JP2024543347A (ja) 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画
JP7838764B2 (ja) 新型コロナウイルス感染症後遺症の治療薬
EP3233825B1 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
JP2024026905A (ja) てんかん治療剤
Smith Muscarinic Acetylcholine Receptor 1: Implications for Precision Medicine and Rett Syndrome Therapeutics
US12472158B2 (en) Methods of treating trigeminal nerve pain
EP3860607B1 (en) Compound (8ar,12as,13as)-5,8,8a,9,10,11,12,12a,13,13a- decaidro-3-methoxy-12-(ethylsulphonyl)-6h- isochino [2,1-g] [1,6] naftiridine for use in the treatment of psychoses
Meng et al. 109P Preserve sense by antisense–a novel allele-specific antisense oligonucleotide therapy for SPTLC1-related hereditary sensory neuropathy
WO2023078807A1 (en) A class iia hdac inhibitor and decitabine to treat myopathy
TW202307217A (zh) 用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法
JP2024537981A (ja) 筋萎縮性側索硬化症を治療する方法
Ristic et al. The influence of the lesion in STN on clinical characteristics of the patients with hemiballism due to stroke

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250818

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230